BRKR · Company research
Bruker Corporation (BRKR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
27records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Bruker Corporation (BRKR) Stock Forecasts - Yahoo Finance | Bruker Corporation (BRKR) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage - Seeking Alpha | Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage Seeking Alpha | View source ↗ | Seeking Alpha | Oct 14, 2026 | neutral | 0 | 0.6 |
| Bruker (NASDAQ:BRKR) Stock Keeps Neutral Rating at JPMorgan Chase & Co. - MarketBeat | Bruker (NASDAQ:BRKR) Stock Keeps Neutral Rating at JPMorgan Chase & Co. MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| Bruker Corporation (BRKR) Stock Price, News, Quote & History - Yahoo! Finance Canada | Bruker Corporation (BRKR) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| Bruker Corp (BRKR) Shares Fall 4.4% -- What GF Score of 83 Tells Investors - GuruFocus | Bruker Corp (BRKR) Shares Fall 4.4% -- What GF Score of 83 Tells Investors GuruFocus | View source ↗ | GuruFocus | Oct 12, 2026 | neutral | 0 | 0.6 |
| 3 Reasons BRKR is Risky and 1 Stock to Buy Instead - Yahoo Finance | 3 Reasons BRKR is Risky and 1 Stock to Buy Instead Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Should Plasma Proteome Atlas Require Action From Bruker (BRKR) Investors? - Simply Wall Street | Should Plasma Proteome Atlas Require Action From Bruker (BRKR) Investors? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| Bruker Corporation (NASDAQ:BRKR) Stock Has Average Target Price of $58.57 According to Brokerages - MarketBeat | Bruker Corporation (NASDAQ:BRKR) Stock Has Average Target Price of $58.57 According to Brokerages MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Bruker (BRKR), Why Is Its Latest Update Drawing Fresh Attention? - Yahoo Finance | Bruker (BRKR), Why Is Its Latest Update Drawing Fresh Attention? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Bruker Gains 66.3% in a Year: What's Driving the Rally? | Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Bruker Gains 66.3% in a Year: What's Driving the Rally? - TradingView | Bruker Gains 66.3% in a Year: What's Driving the Rally? TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| Bruker Gains 66.3% in a Year: What's Driving the Rally? | Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Bruker Gains 66.3% in a Year: What's Driving the Rally? | Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Bruker Corporation (BRKR) Stock Forecasts - Yahoo Finance | Bruker Corporation (BRKR) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overv - GuruFocus | Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overv GuruFocus | View source ↗ | GuruFocus | Oct 6, 2026 | neutral | 0 | 0.6 |
| Bruker Corporation (BRKR) stock price, news, quote and history - Yahoo Finance Singapore | Bruker Corporation (BRKR) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 6, 2026 | neutral | 0 | 0.6 |
| Bruker (NASDAQ:BRKR) Stock Price Down 6.5% - Time to Sell? - MarketBeat | Bruker (NASDAQ:BRKR) Stock Price Down 6.5% - Time to Sell? MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| A blood study found 179,049 different forms of human proteins - Stock Titan | A blood study found 179,049 different forms of human proteins Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Bruker (BRKR) Unveils New Proteomics Tools, Is The Stock Fully Priced? - Simply Wall Street | Bruker (BRKR) Unveils New Proteomics Tools, Is The Stock Fully Priced? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| Are Options Traders Betting on a Big Move in Bruker Stock? | Bruker Corporation (BRKR) is experiencing elevated implied volatility in its December 2026 $75 put options, suggesting traders expect significant price movement. However, the fundamental outlook remains weak, with analysts downgrading estimates over the past 60 days, pushing the consensus estimate down from 55 cents to 42 cents per share. The stock holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bearish | -1 | 1 |
| How New Mass Spectrometry Workflows Will Impact Bruker Stock (BRKR) - Simply Wall Street | How New Mass Spectrometry Workflows Will Impact Bruker Stock (BRKR) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 4, 2026 | neutral | 0 | 0.6 |
| Bruker Stock Price Forecast. Should You Buy BRKR? - StockInvest.us | Bruker Stock Price Forecast. Should You Buy BRKR? StockInvest.us | View source ↗ | StockInvest.us | Oct 2, 2026 | neutral | 0 | 0.6 |
| Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term | Bruker Corporation (BRKR), a life science and materials research systems manufacturer, is highlighted as a momentum investment opportunity despite holding a #3 (Hold) Zacks Rank. The stock has gained 4.3% over the past four weeks and features strong Momentum and VGM Style Scores of A and B respectively. One analyst raised earnings estimates for fiscal 2026, with the consensus estimate at $2.12 per share and an average earnings surprise of +22.7%. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 1 | 1 |
| Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term | Bruker Corporation (BRKR), a life science and materials research systems manufacturer, is highlighted as a momentum investment opportunity despite holding a #3 (Hold) Zacks Rank. The stock has gained 4.3% over the past four weeks and features strong Momentum and VGM Style Scores of A and B respectively. One analyst raised earnings estimates for fiscal 2026, with the consensus estimate at $2.12 per share and an average earnings surprise of +22.7%. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 1 | 1 |
| Bruker (NasdaqGS:BRKR) Stock Forecast & Analyst Predictions - Simply Wall Street | Bruker (NasdaqGS:BRKR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 1, 2026 | neutral | 0 | 0.6 |
| Bruker (BRKR) Stock Trades Down, Here Is Why - StockStory | Bruker (BRKR) Stock Trades Down, Here Is Why StockStory | View source ↗ | StockStory | Aug 4, 2026 | neutral | 0 | 0.6 |
| Bruker (NASDAQ:BRKR) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 11.9% - StockStory | Bruker (NASDAQ:BRKR) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 11.9% StockStory | View source ↗ | StockStory | Aug 4, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.